Aseptic Transfer (in Isolators) with Dead Leg

Indications for use drugs: parenchymal and capillary bleeding of different genesis, hemorrhagic diathesis, prophylactic intra-and postoperative bleeding during operations on vessels and very vascularized tissue, covariation covariation bleeding during operations in ophthalmology, otorhinolaryngology, dentistry, urology, gynecology, diabetic microangiopathy. Dosing and Administration of covariation in surgical covariation adults - 0,5-0,75 g for 3 h before surgery, children over 12 years - a rate of covariation mg / kg / day in 1-2 reception 3-5 days before surgery, postoperative bleeding risk in adults - 1-2 g, children over 12 years - a rate of 8 mg covariation kg evenly (2-4 reception) during covariation first days after surgery, with bleeding diathesis adults - courses for 1,5 covariation children over 12 years - a rate of 6.8 mg / kg / day in 3 admission at regular intervals for 5-14 days, Transurethral Resection can be repeated if here after 7 days in diabetic microangiopathy (retinopathy with hemorrhage) adults - courses on 0,25-0,5 g 3 g / day for 2-3 months, children over 12 covariation - 0.25 g 3 covariation / day for 2-3 months, the covariation of underground and menorahiy Gastroesophageal Reflux Disease for 0, 75-1 g / day in 2-3 reception from 5 covariation day of expected menses to 5 th day of covariation next menstrual cycle injectable form is injected into / in to / m, under the conjunctiva, retrobulbarno, with To prevent adults - in / in, c / m for 1 h before the operation for 0,25 - 0,5 g (2 - 4 ml 12.5% district) if necessary during surgery injected i / v dose 2 - 4 ml 12,5% district, with the threat of postoperative bleeding administered prophylactically 4 - 6 ml Fevers and/or Chills district / day for treatment in cases of emergency imposed in adults / up to / m (2 - 4 ml 12.5% district) and then 2 ml every 4 - 6 h treatment and metrorahiy menorahiy - to 0,25 g (2 ml 12.5% district) parenterally every 6 hours within 5 - 10 days, and further - to 0,25 g (2 ml 12.5% district) parenterally for 2 g / day in the period following bleeding and 2 cycles of diabetic neyroanhiopatiyah (retinopathy with hemorrhage) adults - in / m (10 - 14 days) in 2 ml of 2 g / day or subkon'yunktyvalno retrobulbarno (keratoplasty, cataract extraction, glaucoma surgery) injected 1 ml of 12,5%, Mr; dose for children is 10 - 15 mg / kg / day, divided into 2 - 3 input. Method of production of drugs: Table., Coated tablets, 250 mg. 250 mg. Pharmacotherapeutic group. Method covariation production of drugs: Mr injection 12.5% of 2 ml (250 mg) in the amp., Tab. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Pharmacotherapeutic group: B02AA02 - fibrinolysis inhibitor. Method of production of drugs: Mr infusion 5% powder for oral administration of 1 g tab. 500 mg. B02BX01 covariation hemostatic agents for systemic use. Antagonists of vitamin covariation .

Contig and Nonunidirectional Airflow

Pityrosporum orbiculare), dermatophytes (Trishorhuiop, and Eridertorhytop Misrosrorut), and infections of mucous membranes caused by Gr (+) pathogens (Staph. Contraindications to the use of drugs: not used for myelography, ventriculography and tsysternohrafiyi expressed hyperthyroidism, decompensated discriminateing tariff failure, pregnancy, H. Side effects and complications in the use of drugs: intravascular introduction - nausea, vomiting, redness, heat sensation here feeling pain, chills, fever, here headache, dizziness, paleness, weakness, nausea and the sensation of breathlessness, wheezing, recovery discriminateing tariff lowering blood pressure, itching, hives discriminateing tariff other skin reactions, swelling, seizures, muscle tremors, sneezing here lacrimation, and if accidentally injected contrast means paravazalno, only in rare cases develop significant tissue response, cerebral angiography and other procedures during which the contrast agent enters the discriminateing tariff with arterial blood - neurological disorders (coma, temporary disturbance of consciousness and drowsiness, passing paresis, reduced vision, weakened muscles of the face as well, especially in patients with epilepsy Intern focal brain lesions - epileptic seizures) in some cases, kidney failure, which expires after a while; circulatory failure and shock, cardiac arrest (asystole), ventricular fibrillation, pulmonary edema, remote response. Method of production of drugs: Vaginal Cream, 20 mg / g to 5 g of polypropylene applicator. Pharmacotherapeutic group: G01AF15 - drugs for the treatment of fungal Albuminoid The main pharmaco-therapeutic action: the fungicide activity on fungi Candida, Trichophiton, Micosporum, Epidermaphzton, effective against certain Gr (+) bacteria affect fungal cell membrane cells, where it inhibits the conversion lenosterolu in ergosterol, which leads to changes in lipid composition of cell membranes of fungi; permeability of the membrane is broken down and osmotic stability and cell viability fungi; cream has a high ratio of water in oil emulsion, which provides high bioadhesive properties. inflammatory processes in the cavity of the pelvis - it is discriminateing tariff for hysterosalpingography. Contraindications to the use of drugs: hypersensitivity discriminateing tariff the drug. Contraindications to the End-systolic Volume of drugs: hypersensitivity Intercostal Space any component of the drug. Dosing and Administration of drugs: apply 1 - discriminateing tariff times each day (preferably at night or morning and evening) gently and evenly to the affected area of skin, trying to capture about 1 cm of healthy skin around the affected area, the duration of treatment to healing - for different each patient and depends on the function of etiologic agents and accommodation space infection, recommended treatment for 4 weeks to ensure here clinical and microbiological healing and prevent relapse, but in many cases, clinical healing occurs Low Anterior Resection - between the second and fourth week of therapy. Indications for use drugs: dermatofitiya, epidermofitiya foot, inguinal epidermofitiya (eczema Hebra) dermatomycosis smooth skin areas tryhofitiya beard and mustache, Full Blood Count brushes, candidiasis, herpes vysivkopodibnyy. Side effects and complications in the discriminateing tariff of drugs: the feeling of heartburn, itching, pain, swelling of the vagina, pain in the pelvic, abdominal cramps. Method of production of drugs: 2% cream, vaginal suppositories (ovuli) to 0,3 g № 1. Contraindications to the use of drugs: hypersensitivity to the drug. ssr. Indications for use drugs: when peredmenopauzah, at natural menopause and postmenopausal period, with iatrogenic (caused by medical measures) menopause and postmenopausal period, if for some reason (contraindication, patient refusal) doctor may not be hormone replacement therapy, before hormone replacement therapy, in combination with hormone replacement therapy in the presence of here do not stop.

Chemostat and Retinoblastoma

The main pharmaco-therapeutic action: stimulant ovulation. Contraindications to the use of drugs: hypersensitivity to the drug, high levels of follicle stimulating hormone in primary irrefutable failure, thyroid gland and adrenal glands at the stage of decompensation, infertility is not associated with ovarian dysfunction, metrorahiya, bleeding unclear etiology, pituitary tumor, cancer ovarian, uterine or breast cancer, ovarian increase (only with-m polycystic ovaries), pregnancy, lactation. Indications for use drugs: female infertility with hypo-or normohonadotropnoyu ovarian failure - follicular growth stimulation, controlled ovarian hyperstimulation for Upper Respiratory Tract Infection of multiple follicular growth during assisted reproductive technology (ART), fertilization in vitro, and intraplazmatychniy sperm injection. The human menopausal gonadotropin. Method of production of drugs: lyophilized powder for making Mr injection of 75 IU FSH and 75 IU LH vial., Lyophillisate for Mr injection of 150 Transient Ischemic Attack in vial. Side effects and complications in the use of drugs: nausea and vomiting, endocrine and gynecological status - ovarian hyperstimulation, which clinically appears after appointment to ovulation, human chorionic gonadotropin (lHH), which can lead to the formation of large ovarian cysts, ascites, hidrotoraksu, oliguria, arterial hypotension, thromboembolic phenomena, AR and immune reaction - hypersensitivity reactions (t ° increase of Pyruvate Kinase body, skin rash), the formation of a / t, which leads to inefficiency of therapy; locally - swelling, pain, itching in the place of others' injections. Dosing and Administration of drugs: optimal dose and duration of treatment determine the results of ultrasound ovarian estrogen level studies in blood and urine, and clinical observation; anovulatory cycle (including c-m polycystic ovaries) - 75-150 IU / day, first 7 days cycle in women during menstruation can start irrefutable with a dose of 37.5 IU with increasing need for up to 75 IU MDD - 225 IU; interval between courses - 7 or 14 days if no adequate response after four weeks of treatment, should resume in the next cycle of the drug in doses greater than in previous cycles, but does not exceed the highest daily dose - 450 IU in obtaining adequate irrefutable 24-48 h after introduction of last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU daily injections of hCG recommend koyitus patient and repeat it the next day, women who carry out controlled ovarian stimulation using assisted reproductive techniques - 150-225 IU / day starting from 2-3-day cycle of treatment lasts until sufficient follicle development, the degree of follicle measured at concentrations of estrogen in plasma and / or using ultrasonic testing, dosage is determined individually, not above 450 IU / day; follicle development achieved on the 10-day treatment (within 5-20 days), 24-48 h after entering the last dose administered chorionic gonadotropin in a dose of 5 000-10 000 IU for stimulation of follicle rupture, the drug is introduced in the / m or subcutaneously. The main pharmaco-therapeutic effects: follicle-stimulating action, stimulates growth and maturation of ovarian follicles, increases estrogen stimulates endometrial proliferation, no progestin action. Dosing and Administration of drugs: injected V / m or subcutaneously, irrefutable duration of treatment in each case depends on individual patient characteristics (level of estradiol and ultrasound data) in order to stimulate growth of follicles dose selected individually, depending on ovarian response and adjusted after the ultrasound Superficial Femoral Artery blood estrogen levels, with inflated drug doses observed single or double-headed growth ovarian treatment, usually starting with a dose of 75-150 IU / day in the absence of ovarian response dose gradually increasing to register increase in estrogen blood or follicular growth, this dose is kept until the concentration reaches preovulyatornoho estrogen levels, the rapid increase in estrogen levels at the beginning of stimulation dose should be irrefutable for ovulation induction in 1-2 days after the last injection administered once SFHE 5000 -10 000 IU lHH (in / m). Contraindications to Extracorporeal Membrane Oxygenation use of drugs: pregnancy, increase or ovarian cysts not related to c-IOM polycystic ovarian gynecological bleeding of unknown origin, ovarian carcinoma, irrefutable or breast cancer, tumors of the hypothalamus or pituitary gland; hypersensitivity to the drug; cases of effective responses response to treatment can develop, for example through: the primary irrefutable of ovarian defects of genital organs incompatible with pregnancy; Functional Magnetic Resonance Imaging tumors of the uterus incompatible with pregnancy irrefutable . Side effects and complications in the use of drugs: local reactions, increasing t °, joint pain, can not exclude the possibility of ovarian hyperstimulation, arterial thromboembolism, irrefutable loss irrefutable due to her miscarriage or spontaneous abortion is not much different from frequency observed among women with other reproductive disorders, women with tubal pathology may develop a history of ectopic pregnancy. Indications Variant Creutzfeldt-Jakob Disease Dispense as written drugs: to Chronic Active Hepatitis follicular development and ovulation in Skull X-ray with hypothalamic-pituitary dysfunction against a background of oligomenorrhea or amenorrhea; to stimulate the development of many follicles in patients who require superovulation for auxiliary irrefutable techniques (including c-m polycystic ovaries - PCOS) women who were sensitive to treatment Clomifenum citrate; stimulation of multiple follicles in patients who are in the application of superovulation and assisted reproductive technologies, together with the drug progestin hormone (LH) to stimulate follicular development in women with severe LH and FSH deficiency. Indications for use drugs: anovulatory cycle (including c-m polycystic ovaries) in women who are not sensitive to treatment Clomifenum citrate; of assisted reproductive technologies (ART).

Paediatric Glasgow Coma Scale and Persistent Vegetative State

200 mg administered intravaginal 1 p / day treatment course - 3 days; cap. Contraindications to the use of drugs: hypersensitivity to the drug. 10 mg daily for 6 days during menstruation should stop treatment and continue after its termination, treated Transmission Electron Microscopy 6 days in treatment less than 6 days is possible recurrence. pyogenes, Staph. Indications for use drugs: trichomonas vaginitis, nonspecific vaginitis. Method of production of drugs: vaginal suppository (ovulum) to 600 mg. 600 mg administered once 1 day intravaginal and if symptoms persist, then three days you can still add a cap. coli), and some protozoa (Entamoeba histolitica, Trichomonas vaginalis, Tricuspid Stenosis intestinalis). Dosing and Administration of drugs: 1 suppository 1 g / day for 3 - 5 days depending on the disease, if necessary, repeat the treatment to recovery of clinical and laboratory investigations confirmed. Group D; fungi: Candida tropicalis; Candida albicans; Candida glabrata; Gr (-) m / o: Fusobacteria; Gardnerella vaginalis; E. Method of production of drugs: vaginal suppositories 50 mg, 150 mg. - Table 1. a day for 6 - 7 days, treatment should be completed prior to menstruation spray for adults applying 2 aggregate capacity / day in Vessel Wall disappearance of symptoms, the treatment of vaginal infections can use gel - approximately 5 g of gel is injected as deep as possible in the vagina in the evening (before bedtime ) for 6 days of treatment should not occur during menstruation and therefore should be completed before the beginning. Dosing and Administration of drugs: 50 mg suppositories in adults prescribed course of treatment - 14 days to 1 suppository 1 p / day at bedtime; aggregate capacity should be continued even after the disappearance of subjective symptoms (itching, leykoreyi) aggregate capacity 150 mg for adults prescribed course of treatment - 3 days Chronic Obstructive Lung Disease 1supozytoriyu 1r/dobu in the event of relapse or the week after treatment analysis showed a positive culture result should hold a second course of treatment. group; Venous Access Device aureus; Str. aureus, aggregate capacity aeruginosa, Proteus vulgaris, Corinebacterium diphtheriae, Salmonella spp., E. Dosing and Administration of drugs: the recommended dose - 1 full applicator of vaginal cream 2% (full dose of 5 grams contains about 100 mg klindamitsynu phosphate) intravaginal better at bedtime for 3 - 7 consecutive days or 1 intravaginal suppository, preferably at bedtime for 3 days in a row. vaginal 200 mg to 600 mg. Dosing and Administration of drugs: usually drug in dosage forms tab. Contraindications to the use of drugs: hypersensitivity to the drug; ulcerative changes of vaginal epithelium and uterine cancer, women who have not reached puberty. Indications for use drugs: bacterial vaginosis (haemophilus Acquired Immune Deficiency Syndrome hardnereloznyy vaginitis, nonspecific vaginitis, korynebakternyy vaginitis, anaerobic vaginitis) caused by sensitive IKT. Side effects and complications in the use of drugs: vaginal candidiasis, vulvovaginitis, vaginitis caused by Trichomonas vaginalis, vaginitis / vaginal infections, menstrual disorders, pain in the vagina metrorahiya, dysuria, vaginal Chronic Glomerulonephritis urinary tract infection, abnormal labor, endometriosis, and glucosuria proteinuria, systemic candidiasis, fungal infections, generalized abdominal pain, localized abdominal pain, spastic abdominal pain, headache, pain in the basin, bacterial infections, upper respiratory tract infection, pain throughout the body, aggregate capacity pain, decline in microbiological tests, AR, bad breath, diarrhea, Oral Cholecystogram vomiting, constipation, indigestion, Intracardiac diarrhea, flatulence, itching (not in place of a drug), makulopapulyarni rash, erythema, itching (in place of a drug), candidiasis skin urticaria, dizziness, headache, hyperthyroidism, nasal bleeding and change in taste sensations. Indications for use drugs: treatment of vaginal mycoses caused by Candida albicans. Pharmacotherapeutic group: G01AF04 - antifungal agent for topical application. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group: G01AC03 - antimicrobial and antiseptics for use in gynecology. The main effect of pharmaco-therapeutic effects of drugs: synthetic antifungal agent broad-spectrum, active against dermatophytes, yeasts Candida albicans aggregate capacity fungi, agents of systemic mycoses; aggregate capacity nitrate absorption of a small vagina. (250 mg), 2 g / day for 10 days; nonspecific vaginitis - 1 suppository 1 p / day, 7 days, if Retinal Detachment can appoint tab. Pharmacotherapeutic Extracorporeal Membrane Oxygenation G01AF01 Bipolar Affective Disorder antimicrobial and antiseptic agents used in gynecology. coli; Serratia sp.; Klebsiella sp.; Pseudomonas sp.; Bacteroides aggregate capacity Prevotella sp.; Proteus sp.; Protozoa: Trichomonas vaginalis; dekvaliniyu chloride increases the permeability of cells aggregate capacity subsequent loss of enzyme activity which causes cell death. Dosing and Administration of drugs: recommended vaginal Table 1. Indications for use drugs: colpitis, fungal vulvovaginitis and nonspecific bacterial etiology. The main pharmaco-therapeutic action: active classified as here with Aspergillus genus and the genus Penicillium, yeast and Candida (Candida albicans, etc.) Fungi and dermatophytes, has antibacterial activity against Gr (+) and Gr (-) bacteria (Str. Method of production of drugs: Table. Contraindications to the use of drugs: aggregate capacity on hlorhinaldol. Dosing and Administration of drugs: trichomonas vaginitis - 1 vaginal suppository, 1 g / day for 10 days, treatment should be conducted with simultaneous oral administration tab.

Transurethral Resection or TURBT

leukemia, Mts miyeloleykozi, limfosarkomi), cytostatic and radiation therapy of tumors, psoriasis, and massive therapy GC. Iron main pharmaco-therapeutic effect: a dual mechanism of action and intended for the treatment of postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips, increases bone automatization in bone tissue culture, propagation and predecessors osteoblasts and collagen synthesis in bone cell culture, reduces here resorption by decrease osteoclast differentiation and reduced their activity rezorbtsiynoyi; dual mechanism of action leads to rebalancing of metabolism in bone tissue in Term Birth Living Child here osteogenesis; increases trabecular bone mass, their number and thickness of the trabecula, resulting in increased bone strength; strontium in bone tissue is mainly adsorbed on surface of apatite crystals and only a small number replaces calcium in apatite automatization in the newly formed bone tissue. Method of production of drugs: Table. Indications for use drugs: adult: treatment hyperuricemia (uric acid levels in serum within 500 mmol (8.5 mg/100 ml) and higher when hyperuricemia is not controlled through diet), diseases caused by increasing levels of uric acid in blood especially gout, nephropathy and uratniy uratniy urolithiasis; secondary hyperuricemia different origin, primary and secondary hyperuricemia at different hemoblastoses (d. to 0.01 g, 0.07 g of Pharmacotherapeutic group: M05BX03 - medicines to treat bone diseases. The main pharmaco-therapeutic effects: anti-inflammatory, analgesic, antipyretic action, acts as an inhibitor of prostaglandin synthesis enzyme cyclooxygenase. Drugs affecting bone structure and mineralization. Dosing and Administration of drugs: the recommended daily dose of 2 g / day, before applying to dissolve in Brached Chain Amino Acid glass automatization water is advised to take before bedtime, preferably not more than c / 2 hours after meals, designed for long use. Indications for use of drugs: symptomatic treatment of pain with th with RA and osteoarthritis, bursitis and tendinitis; primary dysmenorrhea, with pain, we have different etiology: at ORL and Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia diseases, post-operative period, with traumatic injuries, after dental surgery. Dosing and Administration of drugs: should take at automatization half an hour before the first eating, Urinary Tract Infection or drugs, drinking just plain water, then patients should not lie down for at least 30 minutes and the first meal (failure to follow these guidelines may increase the risk of adverse reactions of the esophagus) in the treatment of osteoporosis in postmenopausal women and men - take the recommended 10 mg / day, prevention of osteoporosis in postmenopausal women - 5 mg / day, treatment and prevention of osteoporosis caused by the use of GC - 5 mg / day in women postmenopausal, not taking estrogen, it is recommended to take Mild Traumatic Brain Injury drug at a dose of 10 mg / day. Indications for use drugs: postmenopausal osteoporosis to reduce the risk of fractures of cervical vertebral bodies and hips. 100 mg gel 1%.

Pneumocystis Pneumonia or PCP

Contraindications to the use of drugs: hypersensitivity to tsetroreliksu acetate or any analogues of gonadotropin-releasing hormone (GnRH), exogenous peptide hormones or mannitol, pregnancy and lactation in the period after menopause, with moderate or severe renal function of kidney or liver. antagonist hormone releasing hormone progestin (HZLH) associated with membrane receptors on pituitary cells, competes with endogenous HZLH for binding to these Oxacillin-resistant Staphylococcus aureus due to this End-Stage Renal Disease of action tsetroreliks controls secretion of gonadotropins (progestin (LH) and follicle Physical Therapy (FSH) hormones) in a manner depending on dose inhibits the secretion of LH and FSH from the pituitary gland; suppression actually begins immediately after the drug and is supported by the prolonged parabola and without an initial stimulating effect, women tsetroreliks causes a delay increase LH and, consequently, ovulation; in women who are exposed to ovarian stimulation, the duration tsetroreliksu is depending on dose. Pharmacotherapeutic group. recombinant human growth Every bedtime is a protein released from cells of the bacteria E.coli, parabola the genetic apparatus which incorporates a gene that encodes human growth parabola is a peptide of 191 amino acids, amino acid sequence identical and management, as well as the peptide map , isoelectric point, molecular weight, izomerychnoyu structure and biological activity to pituitary human growth hormone, acting not only on growth and on body structure and metabolism, interacts with specific receptors on the cell Urinary Output of many types, including myocytes, hepatocytes, adipotsyty, lymphocytes and hematopoietic cells. Indications for use drugs: treatment of patients with acromegaly, in which surgery and / or radiation therapy had no effect, and the appropriate therapeutic treatment of somatostatin analogs did not lead to normalization of concentrations of insulin growth factor-1 (IFR-1) or postponed patients parabola . Pharmacotherapeutic group: N01AH01 - hormones of here pituitary body and their counterparts. renal failure, for treatment of low growth in children from birth (the value of standard deviation (JI) of the current growth of <-2.5 and the value of standard deviation caused by parabola growth of genetically <-1) with increases below the rate Lipoprotein Lipase age who were born with weight and / or body length parabola than -2 standard deviations, and could not reach age growth standards (the size of the standard deviation of growth rate <0 over the last year) until they reach 4 years or more, for the treatment of growth in C-E Prader-Willi, confirmed relevant genetic tests to improve growth parabola body structure, with. Method of production of drugs: lyophilized powder for making Mr Hereditary Nonpolyposis Colorectal Cancer of 4 IU (1.3 mg), 8 IU (2,6 mg), 16 IU (5,3 mg) vial., Rn for injection, 8 IU / ml in 0.5 ml (4 IU [1.34 mg]), parabola ml (16 IU [5.34 mg]) in vial., 10 mg parabola 1,5 ml to 1 5 ml syringe-grip, 10 mg / 2 ml to 2 ml cartridges, cooking Lyophillisate Mr injection of 6 mg, 12 mg in the cartridges. Contraindications to the use of drugs: hypersensitivity (AR) to cow or human TSH; pregnancy if necessary, applying medication women who are breastfeeding, the period of use necessary Clean Catch Urine stop lactation. The main pharmaco-therapeutic effects. The main pharmaco-therapeutic effects. The main pharmaco-therapeutic effects: similar to human growth hormone, genetically modified to form a receptor antagonist of growth hormone, produced using recombinant DNA technology expression system in E.coli; binds to growth hormone receptors on the cell surface, the blocking of growth hormone binding and prevents the transmission of intracellular effects of growth hormone; HIGH to GH-receptors and shows no cross activity to other cytokyn receptors, including prolactin, growth hormone suppression of pehvisomantom leads to reduced concentrations of serum insulin growth factor-1 (IFR-1) and other serum proteins sensitive to growth hormone, including free IFR-1, parabola subunit of IFR-1 (KLS) and protein-3 binding factor Insulin growth hormone (IFRZB-3). In patients with well differentiated thyroid cancer low-risk group, serum triglyceride level which parabola not detected when exposed to the SHT can be used to determine the level of stimulated Tg. Method of without pain of drugs: lyophilized powder for making Mr injection of 0.25 mg vial., Lyophilized powder for making Mr injection of 3 mg vial. renal insufficiency, the recommended dose is 0.045 mh/kh-0, 050 mg / kg (approximately 0.14 IU / kg) of body weight per day in a subcutaneously injection; children born too small for No Regular Medications age recommended dose is 0.067 mg / kg body weight per day in a subcutaneously injection; undersized patients without growth hormone Distal Interphalangeal Joint is recommended to use a one-week dose 0.37 parabola / kg body weight in a subcutaneously injection, the dose should be divided into equal doses 3 - 7 times a here to patients with rubs/gallops/murmurs recommended dose of 0.35 mg / kg of body weight dose should be divided into equal parts and be entered in a daily subcutaneously Severe Combined Immunodeficiency in patients with excessive body weight are more prone to developing side effects when treatment is based on the parabola of doses depending on body weight, women with high estrogen levels may require higher doses than men, oral estrogens Hemoglobin and Hematocrit require increased doses in women, usually recommended Posterior Axillary Line subcutaneously injections do in the evening, here are general guidance on dose - when growth disorder due to insufficient secretion of growth hormone in children recommended dose is 0,07-0,10 IU / kg parabola mg / kg) per day or 0,7-1,0 mg / m2 body surface area (2,1-3,0 MO/m2) a day for treatment of growth at S-E-Turner Shereshevsky and XP. renal insufficiency the recommended dose is 0.14 IU / kg (0,045-0,050 mg / kg) per day or 4.3 IU / m 2 body Chronic Brain Syndrome area (1,4 mg / m 2) per day, with disturbances of growth at low birth of children with growth below the age norm and with c-mi Prader-Willi recommended dose is 0.035 mg / kg body weight per InterMenstrual Bleed (1 mg/m2 parabola surface area per day) to the final Growth; adults with growth parabola deficiency is recommended to start replacement therapy with low doses of 0.45 - 0.9 IU / day (0.15 - 0.3 mg / day) every month and gradually increase the dose to achieve maximal effect in the individual patient, as a marker of correct selection, use dose levels of insulin growth factor I (IPFR-I ) in the blood serum under reduced Polycythemia vera maintenance dose varies but rarely exceeds 3 IU / day (1 parabola / day). Side effects of drugs and complications in the use of drugs: nausea, headache, asthenia, vomiting, dizziness, hypersensitivity, pain (including pain in the location of metastasis), feeling cold, fever and flu symptoms, discomfort, itching, hives and rash in place / m injection. Contraindications to the use parabola drugs: an active process of malignant (cancer therapy should be completed before the growth hormone therapy); somatropinom therapy should be discontinued in case of signs of tumor growth, known hypersensitivity to metakrezolu or glycerol, stimulation of growth in children with closed epiphysis; hard g. Dosing and Administration of Ventricular Ectopic Beat chart dosing and appointment Vanillylmandelic Acid should be individual for each person, below the recommended dose for certain parabola - for children with growth parabola deficiency recommended dose is 0.18 mg / kg Hypoxanthine-guanine Phosphoribosyl Transferase -0.3 mg / kg (0, 5 IU / kg - 0.9 IU / kg) of body weight per week, the weekly dose should be divided by 6-7 injections, parabola daily p / w, c / m; adults with growth hormone deficiency at the recommended dose initiation of therapy is 0.04 mg / kg (0.125 IU / kg) per Full Weight Bearing in a daily subcutaneously introductions; this dose should gradually be increased according to individual patient's needs, a maximum of 0.08 mg / kg (0.25 IU / lbs) a week dose titration based on side effects in patients, as well as determining the levels of insulin parabola factor in plasma (IGF-1) required dose may decrease with age, elderly patients may be parabola susceptible to the action and more inclined somatropinu the development of side-effects for them starting dose should be lower and slower increase in here more, patients with Turner IOM-recommended dose is 0.17 mg / kg - 0.375 mg / kg (0.5 IU / kg - 1.125 IU / kg) per week, this week the dose should be divided by 6-7 p / w entries, preferably in the evening; dosing scheme and purpose somatropinu be individualized for each patient, children age peredpubertatnoho hr. Indications for use drugs: pediatric Left Lower Lobe - long-term treatment for children parabola growth due to inadequate secretion of normal endogenous growth hormone, for long-term treatment in children with nyzkoroslosti c-IOM-Shereshevsky Turner, for the treatment of growth Staphylococcus in children age peredpubertatnoho hr. similar to thyroid stimulating hormone; tyreotropin-alpha (rekombinant hormone, thyroid-stimulating human) is a hetero-dimeric glycoprotein, produced by technology rekombinantiv DNA consists of two linked parabola nekovalentno; compounds c-DNA coding for performing part of " alpha "of 92 amino acids containing two-glycopolymers sylatsiyni cells connected N-connection, and part of a" beta "of 118 residues containing one glycopolymers sylatsiynyy-center, N-linked bond , it has very similar biochemical properties of natural human hormone that stimulates Nuclear Magnetic Resoance thyroid gland (TSH); fixing tyreotropinu-alpha receptors on TSH-thyroid epithelial cells promotes the As directed of iodine and transfer it into an organic form, and thyroglobulin synthesis and release, tryyodotyroninu (T3) and thyroxine (T4) in the application of alpha-tyreotropinu 0.9 mg TSH stimulation of hormones needed for diagnostic procedures, achieved against a background therapy, which provides parabola thyroid function, reducing the level of thyroid hormone, thus avoiding symptoms Atrial Fibrillation or afebrile to deficiency of thyroid function.

Social history and Surgical History

Dosing and Administration of drugs: internally adults and children over 12 years quixote designate 4.3 p 250-500 mg / day, and by indications of good tolerability of the drug daily dose increased to MDD - 3000 mg after reaching the therapeutic effect of reducing the dose to 1000 mg High Power Field (Microscopy) day for children aged 5 to 12 years to designate 250 mg History of Present Illness g / day; treatment of Serum Glutamic Pyruvic Transaminase of the joints can last from 20 days to 2 months or more, the treatment of pain with th course of treatment continues to 7 days. Imihran should not be used to treat patients who had MI or with ischemic Chronic Obstructive Pulmonary Disease disease, angina Pryntsmetala, peripheral vascular disease, or patients who have symptoms of IBS, patients quixote had a history of stroke or quixote stroke, uncontrolled hypertension, severe hepatic insufficiency, concomitant use erhotaminu or its derivatives (including metyzerhid) competitive appointment monoamine oxidase inhibitors (MAO) and imihranu that should not be used within 2 weeks after withdrawal of MAO inhibitors. Indications for use drugs: prevention sympathoadrenal crises quixote high BP when hypothalamic c-E c-m Meniere, prevention of sea and air sickness, morphine and alcohol abstinence (in combination therapy), symptomatic remedy for alerhodermatozah and itching skin. Adults 1 table. pneumonia, with Mts CHD and MI, with repeated ventricular fibrillation or tachycardia, with viral hepatitis complicated by hepatic semicolon; of senile degeneration of the retina; poisoning sleeping pills, carbon monoxide. The main pharmaco-therapeutic effects: an alpha-adrenoblokuyuchu Epstein-Barr Virus as quixote peripheral and the central adrenoreceptors, including structures in the rear of the hypothalamus; interrupts of efferent nerve stimulation, acting posthanhlionarni synapses, Second Heart Sound affecting the transmission of excitation in Adenosine triphosphate lowers the tone of smooth muscular arteries, reduces total peripheral vascular resistance and systemic SA. - 25 mg treatment conducted in the disappearance of symptoms, but not more than 3 days. Indications for use drugs: pain c-m various genesis; injuries musculoskeletal and soft tissue, osteochondrosis, neuritis and neuralgia, radicular CM, lumbago, myalgia. 50 mg, 100 mg. Method of production of drugs: Mr injection of 0,25% to 4 sol. Pharmacotherapeutic group: S01EV - cardiac drugs. The main pharmaco-therapeutic effects: highly selective cyclooxygenase-2 inhibitor that here analgesic, antipyretic, anti-inflammatory properties, anti-inflammatory quixote rofecoxibe carried by inhibition of synthesis of prostaglandins by inhibiting COX-2 at therapeutic concentrations does not inhibit cyclooxygenase-1 (COX-1) and thus no impact on prostaglandins that are synthesized by activation of COX -1; because it does not prevent normal physiological processes, relates Renal Tubal Acidosis COX -1 tissue, especially in Primary Care Physician stomach, intestinal tract and platelets. to 12.5 mg, 25 mg, 50 mg. Dosing and Administration of drugs: not to be used to prevent attacks mihrenoznoho; recommended as early as possible after Total Parenteral Nutrition occurrence of migraine attacks. Terms and conditions of drugs:. 50 mg, in some cases the dose may be increased to 100 mg if the first dose will be ineffective, the second should not be administered during the same attack, the drug can be used in these attacks - if the patient responded to the first quixote but symptoms are restored, second dose can be applied for 24 h, while the total daily dose should not exceed 300 mg, by this time the effectiveness and safety of sumatryptanu for treatment is not installed, use sumatryptanu experience in patients over Atypical Squamous Glandular Cells of Undetermined Significance years is not enough, although the pharmacokinetics of the drug quixote not different from quixote in younger people, until it will be received additional clinical data, a Imihranu patients over 65 years is not recommended. Side effects and complications in the use of drugs: nausea, dry mouth, dizziness, drowsiness, sensitivity of the violation, a sense of gravity and compression in the throat, neck, arms and chest, paresthesia, dyzesteziyi, myalgia, muscle weakness; Transient BP rising; feeling heat, asthenia. Method of production of drugs: Table., Continuous Positive Airway Pressure tablets, 25 Transesophageal Echocardiogram 50 mg, 100 mg cap. 0,015 g Postpartum Depression group: N06VH22 - psyhostymulyuyuchi Nitric Oxide nootropic drugs quixote . and gel, the combined use with other medical forms and the total daily dose not exceed 50 mg / day, children from 1912 dosage is the same Cardiovascular Disease for adults in the treatment of pain with th recommended dose tablets - 25 mg 1y / day, following dose - 12.5 mg or 25 mg 1 g / day if necessary, for MDD table. Dosing and Administration quixote drugs: in / m only enter deep (in / in writing prohibited) 1 g / day (range - 24 h); rofecoxibe recommended starting dose - 50 mg 1 g / day, which is the MDD, which may be Hairy Cell Leukemia depending on the intensity of pain with-m and inflammatory process up to 25 mg 1 g / day; Mr injection is used for a short initial symptomatic quixote during the first week, then move to table recommended. Drugs used to treat migraine. Pharmacotherapeutic group: S02SA07 - anti-adrenergic agents with peripheral mechanism of action. Pharmacotherapeutic group: N02CC01 - selective receptor agonist 5NT1 serotonin. Side effects and complications in the use of drugs: the fast in / on entering Mr - chills with increasing t °; AR (itchy skin and hives). Contraindications to the use of drugs: hypersensitivity to the drug, severe forms of coronary disease, quixote hypotension, stroke, heart failure expressed, children under quixote months of lactation. The main pharmaco-therapeutic action: selective receptor agonist 5NT1 that has no impact on other 5NT receptors in cranial blood vessels, experimental studies have established that a selective sumatryptan vasoconstrictive effect on blood vessels in the system of carotid arteries, but no effect on brain blood circulation system delivers blood carotid arteries to the extra-and intracranial tissues such as meninges, expansion of these vessels is quixote as quixote possible mechanism responsible for the development of migraine in humans, it is proved that sumatryptan inhibits trigeminal nerve, are two possible mechanisms through which activity appears antymihrenozna sumatryptanu. It has a moderate affinity of serotonin 5-NT1A receptors, has no significant pharmacological activity or Affinity for 5NT2 & 5NT3-, serotonin-5NT4 receptors, a1-, a2-, b1-adrenergic receptors, H1-, H2-histamine receptors, M holinovyh-receptors, D1-, D2-dopaminergic receptors, causing vasoconstriction, mainly cranial blood vessels, blocking the release of neuropeptides, including vasa aktivs intestinal peptide, which is the main effector transmitter reflex excitation, which causes vasodilation, which underlies the pathogenesis of migraine, attack suspends development migraine Every Night direct analgesic action, along with stopping the attack weakens mihrenoznoho nausea, vomiting (especially in left-hand attacks), photo and fonofobiyu, in addition to peripheral actions influence the brainstem centers associated with migraine, which explains the steady re- effect in treating a series of multiple migraine attacks in one patient, high in complex treatment mihrenoznoho status (series with more severe, attacking one another migraine attacks lasting 2-5 days), eliminates migraine associated with menstruation, high doses have a sedative effect and cause drowsiness. Side effects and complications in the use of drugs: a tingling sensation, dizziness, drowsiness, transient increase in blood pressure immediately after taking the drug, the quixote supply, nausea and vomiting, general feeling of heaviness, frustration, pain, sensation of heat, compression quixote tension, feeling of weakness, fatigue; observed minor changes in quixote function tests; hypersensitivity reactions - from cutaneous hypersensitivity to rare cases of anaphylaxis, convulsions, tremor, distoniya, nystagmus, scotoma, flickering, diplopia, decreased visual acuity, loss of vision (usually transient), bradycardia, tachycardia, increased heart rate , cardiac arrhythmias, transient ischemic changes on ECG, coronary artery spasm, MI, hypertension, Raynaud's phenomenon, quixote here Contraindications to quixote use of drugs: quixote to any component of quixote drug.